TG Therapeutics
TGTX on Nasdaq. TG Therapeutics sells BRIUMVI, a multiple sclerosis treatment, to adults with relapsing forms. Market value $8.3bn.
Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.
Should I look at this?
Not a fit for our list right now
Why it could be worth it
See Health care stocks that passed both tests
This is not advice. Check the numbers below.
For every $100 of what the whole company costs, it produced $0.22 of spare cash in the past 12 months. A savings account pays about $4.
You pay 60.5 years of operating profit for the business. The average large US company costs around 18.
Each dollar kept in the business earns 10 cents a year. Above 10 is good.
Quality score: 64 of 100. Price score: 31 of 100. Our list needs 70 on quality and 60 on price.
$52.19 a share, 95% above its 1-year low
Over the past year the price has ranged from $26.76 to $59.30.
Pays no dividend
Prices from Tuesday’s close (6 October).
Five years of cash, in billions
Spare cash swings from quarter to quarter here: $17 million in the past 12 months, a shortfall of $25 million in the year to December 2025.
| Revenue | |||||
| Revenue | $7m | $3m | $234m | $329m | $616m |
| Operating margin | |||||
| Operating margin | -5154.3% | -7839.0% | 8.8% | 12.7% | 20.0% |
| Debt to equity | |||||
| Debt to equity | 0.29 | 1.21 | 0.63 | 1.10 | 0.38 |
| Shares outstanding | |||||
| Shares outstanding | 0.15bn | 0.15bn | 0.16bn | 0.16bn | 0.15bn |
Health checks
- Free cash flow positive0 of 5 years
- Accounting looks honest (Beneish)Not enough data
- Financial strength (Piotroski)4 of 9
- Profit backed by cash (accruals)No
- Debt0.38× equity
- Revenue growth, five yearsStrong, 426.8% a year
- Buying back its own sharesNo, 5% more shares since 2021
The quarter to June 2026
How the business did, compared with the same quarter a year earlier.
- Sales: $240 million last quarter, up 70% on a year ago.
- Profit: $8 million, down 72% on a year ago.
- It keeps 17 cents of each $1 of sales as operating profit, down from 19 cents a year earlier.
- Spare cash over the past 12 months: $17 million. A year earlier it spent $59 million more than it brought in.
- 3% fewer shares than a year ago. Each share owns a bit more of the company.
- Debt is $263 million more than cash, up from $116 million a year ago.
- Sales grew on a year ago in each of the last 4 quarters.
| Quarter to | Amount |
|---|---|
| September 2024 | $84m |
| December 2024 | $108m |
| March 2025 | $121m |
| June 2025 | $141m |
| September 2025 | $162m |
| December 2025 | $193m |
| March 2026 | $205m |
| June 2026 | $240m |
| Quarter to | Amount |
|---|---|
| September 2024 | $4m |
| December 2024 | $23m |
| March 2025 | $5m |
| June 2025 | $28m |
| September 2025 | $391m |
| December 2025 | $23m |
| March 2026 | $20m |
| June 2026 | $8m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 27 February 2026
- Next quarterly (estimated, 10-Q)
- 4 November 2026
Who owns it
1 long-term investor we follow owns it, unchanged from 1 last quarter. 428 funds in all.
- Gotham Asset ManagementJoel Greenblatt
- Value
- $2m
- Share of fund
- <0.1%
| Fund | Value | Share of that fund | Change |
|---|---|---|---|
| Gotham Asset ManagementJoel Greenblatt | $2m | <0.1% |
Largest holders overall
- BlackRock$1.2bn
- Vanguard Portfolio Management$438mCut
- State Street$428mCut
- Vanguard Capital Management$338mCut
- Geode Capital Management$200mAdded
- D. E. Shaw$187mAdded
- Soleus Capital Management, L.P.$161mCut
- Price T Rowe Associates$152mAdded
- Clearbridge Investments$146mCut
- Congress Asset Management$143mAdded
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
3 investors own more than 5%.
- BlackRock, Inc.Passive investor12.8%Since 31 March 2025
- Vanguard Portfolio ManagementPassive investor5.3%Since 31 March 2026
- STATE STREET CORPORATIONPassive investor5.1%+0.4 ptsSince 30 September 2025
- The Vanguard GroupPassive investorSold down below 5%Since 13 March 2026
| Holder | Stake | Since | |
|---|---|---|---|
BlackRock, Inc. Passive investor | 12.8% | 31 March 2025 | |
Vanguard Portfolio Management Passive investor | 5.3% | 31 March 2026 | |
STATE STREET CORPORATION Passive investor | 5.1%+0.4 pts | 30 September 2025 | |
The Vanguard Group Passive investor | Sold down below 5% | 13 March 2026 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
No insider bought shares on the open market in the last 12 months. 2 sold $437,650.
- Charney Laurence NDirectorSold
- Date
- 10 September 2026
- Shares
- 5,000
- Price
- $54.96
- Value
- $274,800
- Echelard YannDirectorSold
- Date
- 24 November 2025
- Shares
- 5,000
- Price
- $32.57
- Value
- $162,850
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 10 September 2026 | Charney Laurence N Director | Sold | 5,000 | $54.96 | $274,800 |
| 24 November 2025 | Echelard Yann Director | Sold | 5,000 | $32.57 | $162,850 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
What could go wrong
- Profits run ahead of cash.
- It isn't cheap on profits: 60.5× operating profit.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.